Zweig-DiMenna Associates’s Pacira BioSciences PCRX Stock Holding History

Zweig-DiMenna Associates’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-105,300	Closed	-$4.3M	–	127
2023 Q1	$4.3M	Sell	105,300 -34,750	-25%	-$1.38M	0.58%	63
2022 Q4	$5.41M	Hold	140,050	–	–	0.79%	49
2022 Q3	$7.45M	Sell	140,050 -24,200	-15%	-$1.35M	1.62%	23
2022 Q2	$9.58M	Sell	164,250 -2,425	-1%	-$159K	1.82%	19
2022 Q1	$12.7M	Sell	166,675 -28,325	-15%	-$1.89M	1.7%	20
2021 Q4	$11.7M	Buy	195,000 +19,962	+11%	+$1.1M	0.95%	46
2021 Q3	$9.8M	Buy	175,038 +2,500	+1%	+$144K	0.68%	61
2021 Q2	$10.5M	Sell	172,538 -10,286	-6%	-$651K	0.63%	67
2021 Q1	$12.8M	Buy	182,824 +44,500	+32%	+$3.18M	0.89%	46
2020 Q4	$8.28M	Buy	138,324 +81,400	+143%	+$4.77M	0.52%	69
2020 Q3	$3.42M	Buy	56,924 +15,000	+36%	+$872K	0.23%	102
2020 Q2	$2.2M	Buy	+41,924	New	+$1.75M	0.23%	91

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Zweig-DiMenna Associates's PCRX Position: Q2 2023 in Review

Zweig-DiMenna Associates sold out of Pacira BioSciences (PCRX) in Q2 2023, closing a stake of 105,300 shares — an estimated $4.3M sold.

Zweig-DiMenna Associates first reported a position in PCRX in Q2 2020 and held it in 12 quarters. The position peaked at $12.8M in Q1 2021. 258 funds tracked by Wall St. Rank hold PCRX as of Q2 2023.

Zweig-DiMenna Associates reported no remaining Pacira BioSciences position as of Q2 2023 after selling out during the quarter.
Zweig-DiMenna Associates sold 105,300 Pacira BioSciences shares in Q2 2023, an estimated $4.3M.
Zweig-DiMenna Associates first reported a position in Pacira BioSciences in Q2 2020 and held it in 12 quarters.
Zweig-DiMenna Associates's Pacira BioSciences position peaked at $12.8M in Q1 2021.
258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2023.

Based on Zweig-DiMenna Associates's 13F filing for Q2 2023, filed 26 Jul 2023.